The global RNA therapeutics and vaccines market size was valued at USD 0.21 billion in 2024 and is predicted to hit around ...
From enzymes and lipid nanoparticles to large-scale process design, four global innovators redefine RNA-based medicine development and delivery.
While mRNA vaccines trigger potent initial immune responses, emerging data suggest they do not generate durable plasma cells, ...
Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for applications across infectious disease, immunology, and other therapeutic areas, and ...
The industry’s mRNA alliance is demanding steady FDA leadership, warning that the current “unprecedented turmoil” at the ...
Industrialized, small batch, and individual RNA therapeutics become practical with “in-a-box” manufacturing technology.
Researchers found that using mental models—visual, verbal, or animated—helps people understand mRNA vaccination science, counter misconceptions, and reduce misinformation spread.
Vaccine-induced false positives are a major roadblock in the development of an HIV vaccine, according to a research team at ...
The mRNA technology that helped end the COVID-19 pandemic may now hold the key to defeating cancer, and it exists because of ...
The first experimental vaccine LungVax for preventing lung cancer in high-risk individuals is entering clinical trials.
ARMR Sciences of New York is trialing a vaccine in the Netherlands to protect against fentanyl-related overdose and death.
Lori Lober is a busy woman. Her Facebook shows a life spent watching American football with her girlfriends and going out for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback